Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85


Azithromycin for the secondary prevention of coronary events.

Grayston JT, Kronmal RA, Jackson LA, Parisi AF, Muhlestein JB, Cohen JD, Rogers WJ, Crouse JR, Borrowdale SL, Schron E, Knirsch C; ACES Investigators..

N Engl J Med. 2005 Apr 21;352(16):1637-45.


Randomized secondary prevention trial of azithromycin in patients with coronary artery disease: primary clinical results of the ACADEMIC study.

Muhlestein JB, Anderson JL, Carlquist JF, Salunkhe K, Horne BD, Pearson RR, Bunch TJ, Allen A, Trehan S, Nielson C.

Circulation. 2000 Oct 10;102(15):1755-60.


Secondary prevention of atherosclerosis through chlamydia pneumoniae eradication (SPACE Trial): a randomised clinical trial in patients with peripheral arterial disease.

Vainas T, Stassen FR, Schurink GW, Tordoir JH, Welten RJ, van den Akker LH, Kurvers HA, Bruggeman CA, Kitslaar PJ.

Eur J Vasc Endovasc Surg. 2005 Apr;29(4):403-11.


Description and status of the azithromycin and coronary events study (ACES).

Jackson LA.

J Infect Dis. 2000 Jun;181 Suppl 3:S579-81.


Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study: a randomized controlled trial.

O'Connor CM, Dunne MW, Pfeffer MA, Muhlestein JB, Yao L, Gupta S, Benner RJ, Fisher MR, Cook TD; Investigators in the WIZARD Study..

JAMA. 2003 Sep 17;290(11):1459-66.


Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome.

Cannon CP, Braunwald E, McCabe CH, Grayston JT, Muhlestein B, Giugliano RP, Cairns R, Skene AM; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators..

N Engl J Med. 2005 Apr 21;352(16):1646-54.


Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group.

Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, Faas FH, Linares E, Schaefer EJ, Schectman G, Wilt TJ, Wittes J.

N Engl J Med. 1999 Aug 5;341(6):410-8.


Azithromycin for the secondary prevention of coronary artery disease: a meta-analysis.

Baker WL, Couch KA.

Am J Health Syst Pharm. 2007 Apr 15;64(8):830-6.


Roxithromycin in prevention of acute coronary syndrome associated with Chlamydia pneumoniae infection: a randomized placebo controlled trial.

Leowattana W, Bhuripanyo K, Singhaviranon L, Akaniroj S, Mahanonda N, Samranthin M, Pokum S.

J Med Assoc Thai. 2001 Dec;84 Suppl 3:S669-75.


Effects of a brief course of azithromycin on soluble cell adhesion molecules and markers of inflammation in survivors of an acute coronary syndrome: A double-blind, randomized, placebo-controlled study.

Hillis GS, Pearson CV, Harding SA, Sutherland S, Ludlam CA, Marioni JC, Prescott RJ, Fox KA, Flapan AD.

Am Heart J. 2004 Jul;148(1):72-9.


Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ.

N Engl J Med. 1995 Nov 16;333(20):1301-7.


Treatment with clarithromycin prior to coronary artery bypass graft surgery does not prevent subsequent cardiac events.

Berg HF, Maraha B, Scheffer GJ, Quarles-van Ufford M, Vandenbroucke-Grauls CM, Peeters MF, Kluytmans JA.

Clin Infect Dis. 2005 Feb 1;40(3):358-65.


A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women.

Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, Hennekens CH, Buring JE.

N Engl J Med. 2005 Mar 31;352(13):1293-304.

Items per page

Supplemental Content

Support Center